Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KRT6A Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | P02538 |
| Other Accession | O95678, NP_005545.1 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 60045 Da |
| Antigen Region | 135-164 aa |
| Gene ID | 3853 |
|---|---|
| Other Names | Keratin, type II cytoskeletal 6A, Cytokeratin-6A, CK-6A, Cytokeratin-6D, CK-6D, Keratin-6A, K6A, Type-II keratin Kb6, Hom s 5, KRT6A, K6A, KRT6D |
| Target/Specificity | This KRT6A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 135-164 amino acids from the N-terminal region of human KRT6A. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | KRT6A Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | KRT6A |
|---|---|
| Synonyms | K6A, KRT6D |
| Function | Epidermis-specific type I keratin involved in wound healing. Involved in the activation of follicular keratinocytes after wounding, while it does not play a major role in keratinocyte proliferation or migration. Participates in the regulation of epithelial migration by inhibiting the activity of SRC during wound repair. |
| Tissue Location | Expressed in the corneal epithelium (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. As many as six of this type II cytokeratin (KRT6) have been identified; the multiplicity of the genes is attributed to successive gene duplication events. The genes are expressed with family members KRT16 and/or KRT17 in the filiform papillae of the tongue, the stratified epithelial lining of oral mucosa and esophagus, the outer root sheath of hair follicles, and the glandular epithelia. This KRT6 gene in particular encodes the most abundant isoform. Mutations in these genes have been associated with pachyonychia congenita. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq].
References
Dereure, O. Ann Dermatol Venereol 137(5):423-424(2010)
Trost, A., et al. Mech. Ageing Dev. 131(5):346-353(2010)
Yang, L., et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 27(1):66-68(2010)
Millar, E.K., et al. J. Clin. Oncol. 27(28):4701-4708(2009)
Bai, Z.L., et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26(5):514-517(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
